Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
A review of the Eisai / Pfizer economic model on the cost-effectiveness of donepezil (June 2010) a report contributing to the PenTAG report “The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatement of Alzheimer’s disease (review of TA111): a systematic review and economic model
Donepezil, rivatigmine, galantamine and memantine for the treatment of Alzheimer’s disease: A review of comments submitted by consultees on the reliability of economic model (March 2009) for TA111